Finance

UNITY GP HLDGS(01539.HK)FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 66.72 million, YoY increase of 87.78% - NewTimeSpace
UNITY GP HLDGS(01539.HK)FY 25/26 Annual Report - Profit Attributable to Shareholders stood at HKD 66.72 million, YoY increase of 87.78%

NewTimeSpace (newtimespace.com) News, July 01, 2026, UNITY GP HLDGS(01539.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 118.69 million, decreased by 24.58% YoY

2026-07-02
UNITY GP HLDGS01539.HKNewTimeSpace
NIU HOLDINGS(08619.HK)FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of HKD 138.85 million, turned into a loss from a profit YoY - NewTimeSpace
NIU HOLDINGS(08619.HK)FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of HKD 138.85 million, turned into a loss from a profit YoY

NewTimeSpace (newtimespace.com) News, July 02, 2026, NIU HOLDINGS(08619.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 77.95 million, decreased by 25.25% YoY

2026-07-02
NIU HOLDINGS08619.HKNewTimeSpace
CA CULTURAL(01566.HK)FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of HKD 99.94 million, loss widened by 202.45% YoY - NewTimeSpace
CA CULTURAL(01566.HK)FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of HKD 99.94 million, loss widened by 202.45% YoY

NewTimeSpace (newtimespace.com) News, July 01, 2026, CA CULTURAL(01566.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 360.44 million, decreased by 1.78% YoY

2026-07-02
CA CULTURAL01566.HKNewTimeSpace
RICHLY FIELD(00313.HK)FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of HKD 213.53 million, loss narrowed by 14.5% YoY - NewTimeSpace
RICHLY FIELD(00313.HK)FY 25/26 Annual Report - Profit Attributable to Shareholders stood at loss of HKD 213.53 million, loss narrowed by 14.5% YoY

NewTimeSpace (newtimespace.com) News, July 02, 2026, RICHLY FIELD(00313.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 41.88 million, decreased by 66% YoY

2026-07-02
RICHLY FIELD00313.HKNewTimeSpace
Insilico Medicine (03696.HK): Strategic Partnership with Takeda for AI-Driven Drug Discovery with Total Value Up to USD 600 Million - NewTimeSpace
Insilico Medicine (03696.HK): Strategic Partnership with Takeda for AI-Driven Drug Discovery with Total Value Up to USD 600 Million

NewTimeSpace News: Insilico Medicine disclosed in a voluntary announcement dated July 2 that the Group has entered into a strategic cooperation with Takeda Pharmaceutical. Leveraging Insilico Medicine’s proprietary end-to-end Pharma.AI platform, both parties will jointly advance candidate drug research and development in therapeutic areas selected by Takeda.

2026-07-02
Insilico Medicine03696.HK
MANYCORE TECH (00068.HK): Grant of 1,130,000 Restricted Share Units to 24 Employees - NewTimeSpace
MANYCORE TECH (00068.HK): Grant of 1,130,000 Restricted Share Units to 24 Employees

NewTimeSpace News: MANYCORE TECH announced on July 2 that pursuant to its post-IPO restricted share unit scheme, the Company granted an aggregate of 1,130,000 restricted share units to 24 eligible employees at a nil subscription price.

2026-07-02
MANYCORE TECH00068.HK
People's Insurance Company of China Group (01339.HK): Appointment Qualification of Vice President Zhang Daoming Approved by the State Administration of Financial Regulation - NewTimeSpace
People's Insurance Company of China Group (01339.HK): Appointment Qualification of Vice President Zhang Daoming Approved by the State Administration of Financial Regulation

NewTimeSpace News: PICC Group announced on July 2 that the Company has recently received an official reply from the State Administration of Financial Regulation, approving the appointment qualification of Mr. Zhang Daoming as Vice President of the Company.

2026-07-02
Peoples Insurance Company of China Group01339.HK
Laekna, Inc.(02105.HK): Proposed Share Buyback Plus Senior Management Share Purchases Up to Aggregate HK$56 Million - NewTimeSpace
Laekna, Inc.(02105.HK): Proposed Share Buyback Plus Senior Management Share Purchases Up to Aggregate HK$56 Million

NewTimeSpace News: Laekna, Inc. disclosed in a voluntary announcement dated July 2 that its Board of Directors approved an on-market share repurchase programme on July 1, 2026. Meanwhile, Dr. Lü Xiangyang, Chairman of the Board, and several senior management members plan to concurrently increase their holdings in the Company. The total maximum amount for the on-market buyback and senior management share purchases combined will be HK$56 million.

2026-07-02
Laekna, Inc.02105.HK
SF Intra-city (09699.HK): Total 19.11 Million Shares Purchased under H-Share Incentive Scheme at Total Cost of Approximately HK$193 Million - NewTimeSpace
SF Intra-city (09699.HK): Total 19.11 Million Shares Purchased under H-Share Incentive Scheme at Total Cost of Approximately HK$193 Million

NewTimeSpace News: In a voluntary announcement dated July 2, SF Intra-city disclosed that between 1 September 2025 and 30 June 2026, the trustee purchased an aggregate of 19,113,800 shares in the market under the 2025 H-Share Incentive Scheme, at a total consideration of approximately HK$193 million.

2026-07-02
SF INTRA-CITY09699.HK
Abbisko(02256.HK): Strategic Cooperation Reached with AstraZeneca to Advance Clinical Study of ABSK043 Combined with Tagrisso for NSCLC Treatment - NewTimeSpace
Abbisko(02256.HK): Strategic Cooperation Reached with AstraZeneca to Advance Clinical Study of ABSK043 Combined with Tagrisso for NSCLC Treatment

NewTimeSpace News: In a voluntary announcement dated July 2, Abbisko disclosed that its subsidiary HORIZON Therapeutics entered into a strategic cooperation agreement with AstraZeneca to jointly conduct a multicenter, open-label Phase I/II clinical trial. The trial is designed to evaluate the safety and efficacy of ABSK043 (lumipodlin), the company’s proprietary first-in-class oral small-molecule PD-L1 inhibitor, in combination with AstraZeneca’s third-generation EGFR-TKI Tagrisso (osimertinib) for patients with EGFR-mutated, PD-L1-positive non-small cell lung cancer (NSCLC).

2026-07-02
Abbisko02256.HK
Ribo Life Science(06938.HK): Milestone Achieved with Selection of First Candidate Drug under Collaboration with Madrigal - NewTimeSpace
Ribo Life Science(06938.HK): Milestone Achieved with Selection of First Candidate Drug under Collaboration with Madrigal

NewTimeSpace News: In a voluntary announcement dated July 2, Ribo Life Sciencedisclosed that the milestone of selecting the first candidate drug under its siRNA collaboration programme with Madrigal Pharmaceuticals has been accomplished, and IND-enabling studies will be launched immediately afterwards.

2026-07-02
Ribo Life Science06938.HK
Ganfeng Lithium (01772.HK): Shareholder Wang Xiaoshen Pledges 5.7 Million Shares, Cumulative Pledge Ratio Accounts for 46.96% of His Shareholding - NewTimeSpace
Ganfeng Lithium (01772.HK): Shareholder Wang Xiaoshen Pledges 5.7 Million Shares, Cumulative Pledge Ratio Accounts for 46.96% of His Shareholding

NewTimeSpace News: Ganfeng Lithium announced on July 2 that Mr. Wang Xiaoshen, a shareholder of the Company, pledged 5.7 million shares of the Company to Guotai Haitong Securities. The pledged shares account for 4.03% of his personal shareholding and 0.27% of the Company’s total issued share capital.

2026-07-02
Ganfeng Lithium01772.HK
SSY Group Limited(02005.HK): Methocarbamol Tablets Approved for Marketing; Phloroglucinol API Granted Registration - NewTimeSpace
SSY Group Limited(02005.HK): Methocarbamol Tablets Approved for Marketing; Phloroglucinol API Granted Registration

NewTimeSpace News: In a voluntary announcement dated July 2, SSY Group Limiteddisclosed that the Group has obtained the drug manufacturing registration approval for Methocarbamol Tablets (0.5g) issued by the National Medical Products Administration (NMPA). Meanwhile, the Group’s phloroglucinol active pharmaceutical ingredient (API) has been approved for registration as an API for use in marketed pharmaceutical preparations.

2026-07-02
SSY Group Limited02005.HK
Leads Biolabs(09887.HK): Grant of 2,254,691 H-share Awards to 149 Grantees - NewTimeSpace
Leads Biolabs(09887.HK): Grant of 2,254,691 H-share Awards to 149 Grantees

NewTimeSpace News: Leads Biolabsannounced on July 1 that pursuant to its H-share incentive scheme, the Company granted an aggregate of 2,254,691 share awards to 149 grantees.

2026-07-02
Leads Biolabs09887.HK
CIMC Group (02039.HK): CPIC Prudential Life’s Shareholding Falls Below 5% - NewTimeSpace
CIMC Group (02039.HK): CPIC Prudential Life’s Shareholding Falls Below 5%

NewTimeSpace News: CIMC Group announced on July 1 that CPIC Prudential Life, previously a shareholder holding more than 5% of the Company’s shares, reduced its holdings by disposing of 23,017,066 A-shares via centralized bidding trading between June 24 and June 29, 2026. Following the disposal, its shareholding ratio dropped from 5.43% to approximately 4.9999987%, ceasing to be a shareholder with a stake exceeding 5%.

2026-07-02
CIMC Group02039.HK
JL MAG Rare-Earth (06680.HK): Expected Net Profit Growth of 31% to 51% for First Half - NewTimeSpace
JL MAG Rare-Earth (06680.HK): Expected Net Profit Growth of 31% to 51% for First Half

NewTimeSpace News: JL MAG Rare-Earth released its 2026 half-year performance forecast on July 1, projecting net profit attributable to shareholders of the listed company ranging from RMB 400 million to RMB 460 million for the first half, representing a year-on-year increase of 31.17% to 50.84%.

2026-07-02
JL MAG Rare-Earth06680.HK
Previous1..240241 242243244..359     359 pages total